D. Walsh and D. Selkoe, Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease, Neuron, vol.44, issue.1, pp.181-93, 2004.
DOI : 10.1016/j.neuron.2004.09.010

H. Akiyama, S. Barger, S. Barnum, B. Bradt, J. Bauer et al., Inflammation and Alzheimer's disease, Neurobiology of Aging, vol.21, issue.3, pp.383-421, 2000.
DOI : 10.1016/S0197-4580(00)00124-X

F. Laferla, K. Green, and S. Oddo, Alzheimer's disease, pp.499-509, 2007.

D. Walsh and D. Selkoe, A? Oligomers ? a decade of discovery, Journal of Neurochemistry, vol.279, issue.5, pp.1172-84, 2007.
DOI : 10.1038/nn1630

J. Kuret, C. Chirita, E. Congdon, T. Kannanayakal, G. Li et al., Pathways of tau fibrillization, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol.1739, issue.2-3, pp.167-78, 2005.
DOI : 10.1016/j.bbadis.2004.06.016

C. Haass and D. Selkoe, Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid ??-peptide, Nature Reviews Molecular Cell Biology, vol.26, issue.2, pp.101-113, 2007.
DOI : 10.1038/nrm2101

C. Ballatore, V. Lee, and J. Trojanowski, Tau-mediated neurodegeneration in Alzheimer's disease and related disorders, Nature Reviews Neuroscience, vol.4, issue.9, pp.663-72, 2007.
DOI : 10.1096/fj.04-3620rev

K. Herrup, Reimagining Alzheimer's Disease--An Age-Based Hypothesis, Journal of Neuroscience, vol.30, issue.50, pp.16755-62, 2010.
DOI : 10.1523/JNEUROSCI.4521-10.2010

C. Glass, K. Saijo, B. Winner, M. Marchetto, and F. Gage, Mechanisms Underlying Inflammation in Neurodegeneration, Cell, vol.140, issue.6, pp.918-952, 2010.
DOI : 10.1016/j.cell.2010.02.016

P. Mcgeer, K. Yasojima, and E. Mcgeer, Association of interleukin-1?? polymorphisms with idiopathic Parkinson's disease, Neuroscience Letters, vol.326, issue.1, pp.67-76, 2002.
DOI : 10.1016/S0304-3940(02)00300-2

P. Mcgeer, COX-2 and ALS, Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, vol.2, issue.3, pp.121-123, 2001.
DOI : 10.1080/146608201753275562

P. Mcgeer, M. Schulzer, and E. Mcgeer, Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies, Neurology, vol.47, issue.2, pp.425-457, 1996.
DOI : 10.1212/WNL.47.2.425

S. Vlad, D. Miller, N. Kowall, and D. Felson, Protective effects of NSAIDs on the development of Alzheimer disease, Neurology, vol.70, issue.19, pp.701672-701679, 2008.
DOI : 10.1212/01.wnl.0000311269.57716.63

W. Stewart, C. Kawas, M. Corrada, and E. Metter, Risk of Alzheimer's disease and duration of NSAID use, Neurology, vol.48, issue.3, pp.626-658, 1997.
DOI : 10.1212/WNL.48.3.626

W. Griffin, J. Sheng, M. Royston, S. Gentleman, J. Mckenzie et al., Glial-Neuronal Interactions in Alzheimer's Disease: The Potential Role of a ???Cytokine Cycle??? in Disease Progression, Brain Pathology, vol.39, issue.1, pp.65-72, 1998.
DOI : 10.1111/j.1750-3639.1998.tb00136.x

P. Mcgeer, H. Akiyama, T. Kawamata, T. Yamada, D. Walker et al., Immunohistochemical localization of beta-amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy, Journal of Neuroscience Research, vol.16, issue.3, pp.31428-31470, 1992.
DOI : 10.1002/jnr.490310305

M. Heneka, O. Banion, and M. , Inflammatory processes in Alzheimer's disease, Journal of Neuroimmunology, vol.184, issue.1-2, pp.69-91, 2007.
DOI : 10.1016/j.jneuroim.2006.11.017

R. Giri, S. Selvaraj, C. Miller, F. Hofman, S. Yan et al., Effect of endothelial cell polarity on beta -amyloid-induced migration of monocytes across normal and AD endothelium, AJP: Cell Physiology, vol.283, issue.3, pp.895-904, 2002.
DOI : 10.1152/ajpcell.00293.2001

S. Fuller, G. Münch, and M. Steele, Activated astrocytes: a therapeutic target in Alzheimer???s disease?, Expert Review of Neurotherapeutics, vol.9, issue.11, pp.1585-94, 2009.
DOI : 10.1586/ern.09.111

Q. Wu, C. Combs, S. Cannady, D. Geldmacher, and K. Herrup, Beta-amyloid activated microglia induce cell cycling and cell death in cultured cortical neurons, Neurobiology of Aging, vol.21, issue.6, pp.797-806, 2000.
DOI : 10.1016/S0197-4580(00)00219-0

T. Wyss-coray, Inflammation in Alzheimer disease: driving force, bystander or beneficial response, Nat Med, vol.12, issue.9, pp.1005-1020, 2006.

P. Chakrabarty, A. Li, C. Ceballos-diaz, J. Eddy, C. Funk et al., IL-10 Alters Immunoproteostasis in APP Mice, Increasing Plaque Burden and Worsening Cognitive Behavior, Neuron, vol.85, issue.3, pp.85519-85552, 2015.
DOI : 10.1016/j.neuron.2014.11.020

R. Schmidt, H. Schmidt, J. Curb, K. Masaki, L. White et al., Early inflammation and dementia: A 25-year follow-up of the Honolulu-Asia aging study, Annals of Neurology, vol.51, issue.2, pp.168-74, 2002.
DOI : 10.1002/ana.10265

M. Engelhart, M. Geerlings, J. Meijer, A. Kiliaan, A. Ruitenberg et al., Inflammatory Proteins in Plasma and the Risk of Dementia, Archives of Neurology, vol.61, issue.5, pp.61668-72, 2004.
DOI : 10.1001/archneur.61.5.668

N. Dunn, M. Mullee, V. Perry, and C. Holmes, Association between Dementia and Infectious Disease, Alzheimer Disease & Associated Disorders, vol.19, issue.2, pp.91-95, 2005.
DOI : 10.1097/01.wad.0000165511.52746.1f

P. Aisen, K. Schafer, M. Grundman, E. Pfeiffer, M. Sano et al., Effects of Rofecoxib or Naproxen vs Placebo on Alzheimer Disease Progression, JAMA, vol.289, issue.21, pp.2892819-2892845, 2003.
DOI : 10.1001/jama.289.21.2819

L. Thal, S. Ferris, L. Kirby, G. Block, C. Lines et al., A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment, Neuropsychopharmacology, vol.10, issue.6, pp.301204-301219, 2005.
DOI : 10.1038/sj.npp.1300690

J. Breitner, L. Baker, T. Montine, C. Meinert, C. Lyketsos et al., Extended results of the Alzheimer???s disease anti-inflammatory prevention trial, Alzheimer's & Dementia, vol.7, issue.4, pp.402-413, 2011.
DOI : 10.1016/j.jalz.2010.12.014

H. Crystal, D. Dickson, P. Fuld, D. Masur, R. Scott et al., Clinico-pathologic studies in dementia: Nondemented subjects with pathologically confirmed Alzheimer's disease, Neurology, vol.38, issue.11, pp.381682-381689, 1988.
DOI : 10.1212/WNL.38.11.1682

L. Lue, L. Brachova, W. Civin, and R. J. , Inflammation, A beta deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration, J Neuropathol Exp Neurol, issue.10, pp.551083-551091, 1996.

C. Schwab, M. Hosokawa, and P. Mcgeer, Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease, Experimental Neurology, vol.188, issue.1, pp.52-64, 2004.
DOI : 10.1016/j.expneurol.2004.03.016

A. Cagnin, D. Brooks, A. Kennedy, R. Gunn, R. Myers et al., In-vivo measurement of activated microglia in dementia, The Lancet, vol.358, issue.9280, pp.358461-358468, 2001.
DOI : 10.1016/S0140-6736(01)05625-2

C. Lee and G. Landreth, The role of microglia in amyloid clearance from the AD brain, Journal of Neural Transmission, vol.93, issue.Pt 2, pp.949-60, 2010.
DOI : 10.1007/s00702-010-0433-4

S. Grathwohl, R. Kä-lin, T. Bolmont, S. Prokop, G. Winkelmann et al., Formation and maintenance of Alzheimer???s disease beta-amyloid plaques in the absence of microglia, e-Neuroforum, vol.16, issue.1, pp.121361-121364, 2009.
DOI : 10.1515/nf-2010-0107

J. Sheng, R. Mrak, and W. Griffin, Neuritic plaque evolution in Alzheimer's disease is accompanied by transition of activated microglia from primed to enlarged to phagocytic forms, Acta Neuropathologica, vol.94, issue.1, pp.1-5, 1997.
DOI : 10.1007/s004010050664

W. Streit, Microglial senescence: does the brain's immune system have an expiration date?, Trends in Neurosciences, vol.29, issue.9, pp.506-516, 2006.
DOI : 10.1016/j.tins.2006.07.001

D. Krstic, A. Madhusudan, J. Doehner, P. Vogel, T. Notter et al., Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice, Journal of Neuroinflammation, vol.358, issue.1, p.151, 2012.
DOI : 10.1186/1742-2094-9-151

L. Matsuda, S. Lolait, M. Brownstein, A. Young, and T. Bonner, Structure of a cannabinoid receptor and functional expression of the cloned cDNA, Nature, vol.346, issue.6284, pp.346561-346565, 1990.
DOI : 10.1038/346561a0

S. Munro, K. Thomas, and M. Abu-shaar, Molecular characterization of a peripheral receptor for cannabinoids, Nature, vol.365, issue.6441, pp.36561-36566, 1993.
DOI : 10.1038/365061a0

R. Pertwee, Receptors and Channels Targeted by Synthetic Cannabinoid Receptor Agonists and Antagonists, Current Medicinal Chemistry, vol.17, issue.14, pp.1360-81, 2010.
DOI : 10.2174/092986710790980050

M. Herkenham, B. Groen, A. Lynn, D. Costa, B. Richfield et al., Neuronal localization of cannabinoid receptors and second messengers in mutant mouse cerebellum, Brain Research, vol.552, issue.2, pp.301-311, 1991.
DOI : 10.1016/0006-8993(91)90096-E

E. Núñez, C. Benito, M. Pazos, A. Barbachano, O. Fajardo et al., receptors are expressed by perivascular microglial cells in the human brain: An immunohistochemical study, Synapse, vol.193, issue.4, pp.208-221, 2004.
DOI : 10.1002/syn.20050

M. Van-sickle, M. Duncan, P. Kingsley, A. Mouihate, P. Urbani et al., Identification and Functional Characterization of Brainstem Cannabinoid CB2 Receptors, Science, vol.310, issue.5746, pp.310329-310361, 2005.
DOI : 10.1126/science.1115740

J. Ashton, D. Friberg, C. Darlington, and P. Smith, Expression of the cannabinoid CB2 receptor in the rat cerebellum: An immunohistochemical study, Neuroscience Letters, vol.396, issue.2, pp.113-119, 2006.
DOI : 10.1016/j.neulet.2005.11.038

T. Bisogno, A. Ligresti, D. Marzo, and V. , The endocannabinoid signalling system: Biochemical aspects, Pharmacology Biochemistry and Behavior, vol.81, issue.2, pp.224-262, 2005.
DOI : 10.1016/j.pbb.2005.01.027

D. Piomelli, The molecular logic of endocannabinoid signalling, Nature Reviews Neuroscience, vol.4, issue.11, pp.873-84, 2003.
DOI : 10.1038/nrn1247

C. Vaughan and M. Christie, Retrograde Signalling by Endocannabinoids, Handb Exp Pharmacol, issue.168, pp.367-83, 2005.
DOI : 10.1007/3-540-26573-2_12

D. Prentiss, R. Power, G. Balmas, G. Tzuang, and D. Israelski, Patterns of Marijuana Use Among Patients With HIV/AIDS Followed in a Public Health Care Setting, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.35, issue.1, pp.38-45, 2004.
DOI : 10.1097/00126334-200401010-00005

D. Walsh, K. Nelson, and F. Mahmoud, Established and potential therapeutic applications of cannabinoids in oncology, Support Care Cancer, vol.11, issue.3, pp.137-180, 2003.

K. Maresz, G. Pryce, E. Ponomarev, G. Marsicano, J. Croxford et al., Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells, Nature Medicine, vol.7, issue.4, pp.492-499, 2007.
DOI : 10.1038/nm1561

E. Eljaschewitsch, A. Witting, C. Mawrin, T. Lee, P. Schmidt et al., The Endocannabinoid Anandamide Protects Neurons during CNS Inflammation by Induction of MKP-1 in Microglial Cells, Neuron, vol.49, issue.1, pp.67-79, 2006.
DOI : 10.1016/j.neuron.2005.11.027

Y. Marchalant, F. Cerbai, H. Brothers, and G. Wenk, Cannabinoid receptor stimulation is anti-inflammatory and improves memory in old rats, Neurobiology of Aging, vol.29, issue.12, pp.1894-901, 2008.
DOI : 10.1016/j.neurobiolaging.2007.04.028

Y. Marchalant, H. Brothers, and G. Wenk, Cannabinoid agonist WIN-55,212-2 partially restores neurogenesis in the aged rat brain, Molecular Psychiatry, vol.168, issue.12, pp.1068-1077, 2009.
DOI : 10.1016/j.psyneuen.2007.04.014

Y. Marchalant, H. Brothers, G. Norman, K. Karelina, D. A. Wenk et al., Cannabinoids attenuate the effects of aging upon neuroinflammation and neurogenesis, Neurobiology of Disease, vol.34, issue.2, pp.300-307, 2009.
DOI : 10.1016/j.nbd.2009.01.014

Y. Marchalant, S. Rosi, and G. Wenk, Anti-inflammatory property of the cannabinoid agonist WIN-55212-2 in a rodent model of chronic brain inflammation, Neuroscience, vol.144, issue.4, pp.1516-1538, 2007.
DOI : 10.1016/j.neuroscience.2006.11.016

B. Ramí-rez, C. Blá-zquez, G. Del-pulgar, T. Guzmá-n, M. De-ceballos et al., Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation, J Neurosci, issue.8, pp.251904-251917, 2005.

M. Solas, P. Francis, R. Franco, and M. Ramirez, CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients, Neurobiology of Aging, vol.34, issue.3, pp.805-813, 2013.
DOI : 10.1016/j.neurobiolaging.2012.06.005

C. Benito, E. Núñez, R. Tolón, E. Carrier, A. Rá-bano et al., Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains, J Neurosci, issue.35, pp.2311136-2311177, 2003.

J. Lee, G. Agacinski, J. Williams, G. Wilcock, M. Esiri et al., Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex, Neurochemistry International, vol.57, issue.8, pp.57985-57994, 2010.
DOI : 10.1016/j.neuint.2010.10.010

J. Mulder, M. Zilberter, S. Pasquaré, A. Alpá-r, G. Schulte et al., Molecular reorganization of endocannabinoid signalling in Alzheimer's disease, Brain, vol.134, issue.4, pp.1341041-60, 2011.
DOI : 10.1093/brain/awr046

N. Milton, Anandamide and noladin ether prevent neurotoxicity of the human amyloid-?? peptide, Neuroscience Letters, vol.332, issue.2, pp.127-157, 2002.
DOI : 10.1016/S0304-3940(02)00936-9

X. Chen, J. Zhang, and C. Chen, Endocannabinoid 2-arachidonoylglycerol protects neurons against ??-amyloid insults, Neuroscience, vol.178, pp.159-68, 2011.
DOI : 10.1016/j.neuroscience.2011.01.024

B. Harvey, K. Ohlsson, J. V. Må-Å-g, I. Musgrave, and S. Smid, Contrasting protective effects of cannabinoids against oxidative stress and amyloid-?? evoked neurotoxicity in vitro, NeuroToxicology, vol.33, issue.1, pp.138-184, 2012.
DOI : 10.1016/j.neuro.2011.12.015

E. Janefjord, J. V. Må-Å-g, B. Harvey, and S. Smid, Cannabinoid Effects on ?? Amyloid Fibril and Aggregate Formation, Neuronal and Microglial-Activated Neurotoxicity In Vitro, Cellular and Molecular Neurobiology, vol.129, issue.Pt 11, pp.31-42, 2014.
DOI : 10.1007/s10571-013-9984-x

G. Esposito, D. Filippis, D. Steardo, L. Scuderi, C. Savani et al., CB1 receptor selective activation inhibits beta-amyloid-induced iNOS protein expression in C6 cells and subsequently blunts tau protein hyperphosphorylation in co-cultured neurons, Neurosci Lett, issue.3, pp.404342-404348, 2006.

M. Sciences, M. Stelt, . Van-der, C. Mazzola, G. Esposito et al., Endocannabinoids and ? -amyloid-induced neurotoxicity in vivo : effect of pharmacological elevation of endocannabinoid levels, pp.1410-1434, 2006.

M. Haghani, M. Janahmadi, and M. Shabani, Protective effect of cannabinoid CB1 receptor activation against altered intrinsic repetitive firing properties induced by A?? neurotoxicity, Neuroscience Letters, vol.507, issue.1, pp.33-40, 2011.
DOI : 10.1016/j.neulet.2011.11.044

J. Wu, B. Bie, H. Yang, J. Xu, D. Brown et al., Activation of the CB2 receptor system reverses amyloid-induced memory deficiency, Neurobiology of Aging, vol.34, issue.3, pp.791-804, 2013.
DOI : 10.1016/j.neurobiolaging.2012.06.011

A. Martí-n-moreno, D. Reigada, B. Ramí-rez, R. Mechoulam, N. Innamorato et al., Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease, Mol Pharmacol, issue.6, pp.79964-73, 2011.

G. Fakhfouri, A. Ahmadiani, R. Rahimian, A. Grolla, F. Moradi et al., WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-?? pathway, Neuropharmacology, vol.63, issue.4, pp.653-66, 2012.
DOI : 10.1016/j.neuropharm.2012.05.013

E. Aso, E. Palomer, S. Juvé-s, R. Maldonado, F. Muñoz et al., CB1 agonist ACEA protects neurons and reduces the cognitive impairment of A?PP/PS1 mice, J Alzheimers Dis, vol.30, issue.2, pp.439-59, 2012.

E. Aso, S. Juvé-s, R. Maldonado, and I. Ferrer, CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in A?PP/PS1 mice, J Alzheimers Dis, vol.35, issue.4, pp.847-58, 2013.

A. Martí-n-moreno, B. Brera, C. Spuch, E. Carro, L. Garcí-a-garcí-a et al., Prolonged oral cannabinoid administration prevents neuroinflammation, lowers ?-amyloid levels and improves cognitive performance in Tg APP 2576 mice, J Neuroinflammation, vol.9, p.8, 2012.